SB
SBFM.US Sunshine Biopharma Inc
- Market cap
- USD 2.07M
- P/E
- -
- P/B
- 0.08x
- ROE
- -18.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SBFM.US undervalued?
Graham numberThe Graham number of Sunshine Biopharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sunshine Biopharma Inc fundamental analysis
No fundamental analysis for Sunshine Biopharma Inc yet.
Sunshine Biopharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sunshine Biopharma Inc
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under …
Full company profileSunshine Biopharma Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sunshine Biopharma Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 447K | 21.1K | 71.4K | 228K | 4.35M | 24.1M | 34.9M | 36.3M | 35.7M |
| Gross Profit | -60.7K | -6.63K | 56.1K | 10.1K | 45.6K | 111K | 1.70M | 8.34M | 10.7M | 11.9M | 10.2M |
| Operating Income | -993K | -857K | -1.17M | -642K | -577K | -2.44M | -8.67M | -4.79M | -5.81M | -4.48M | -5.73M |
| EBITDA | -932K | -929K | -1.99M | -948K | -2.60M | -12.1M | -26.4M | -3.82M | -5.14M | -5.62M | -5.22M |
| Net Income | -3.50M | -1.04M | -2.16M | -1.66M | -2.78M | -12.4M | -26.7M | -4.51M | -5.13M | -5.98M | -5.38M |
| EPS | -1,314,544 | -4,772 | -28,370 | -184,477 | -696,023 | -1,776,635 | -703,801 | -73,870 | -1,463 | -287 | -23 |
| Balance Sheet | |||||||||||
| Total Assets | 64.4K | 257K | 1.15M | 98.1K | 1.05M | 2.20M | 29.5M | 27.3M | 30.6M | 30.1M | 33.9M |
| Total Liabilities | 274K | 831K | 1.20M | 834K | 2.00M | 1.99M | 7.92M | 6.14M | 7.06M | 7.04M | 5.22M |
| Shareholders' Equity | -210K | -573K | -55.8K | -735K | -955K | 212K | 21.6M | 21.2M | 23.5M | 23.0M | 28.6M |
| Cash & Short-term Investments | 57.5K | 108K | 115K | 48.1K | 997K | 2.05M | 21.8M | 16.3M | 9.69M | 9.12M | 14.6M |
| Total Debt | 237K | 802K | 953K | 716K | 1.91M | 1.90M | 765K | 658K | 952K | 812K | 628K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -314K | -544K | -513K | -496K | -657K | -1.83M | -5.25M | -8.78M | -12.5M | -5.33M | -5.83M |
| Capital Expenditure | 3.44K | 3.72K | 18.9K | 860.00 | 1.19K | 2.00 | 305K | 788K | 2.32M | 174K | 13.7K |
| Free Cash Flow | -318K | -547K | -532K | -497K | -658K | -1.83M | -5.55M | -9.56M | -14.9M | -5.51M | -5.83M |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | -5,875.6% | -123.7% | -21.2% | -21.8% | -25.9% | -18.8% |
| ROA | -5,429.3% | -404.0% | -188.1% | -1,691.7% | -266.3% | -564.6% | -90.5% | -16.5% | -16.8% | -19.9% | -15.9% |
| Net Profit Margin | - | - | -482.1% | -7,860.9% | -3,898.7% | -5,444.4% | -615.4% | -18.7% | -14.7% | -16.5% | -15.0% |
| Debt to Equity | - | - | - | - | - | 8.98x | 0.04x | 0.03x | 0.04x | 0.04x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sunshine Biopharma Inc dividends
Sunshine Biopharma Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Oct 26, 2026.
Who owns Sunshine Biopharma Inc
- Insiders 5.94%
- Institutions 7.71%
- Public & others 86.35%
- Shares outstanding 824K
- Free float 616K
Top funds holding SBFM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Stewardship Partners US Multifactor | 4.19K | 0.20% | 0.00% | Jun 2026 |
| Stewardship Partners Global Multifactor | 1.69K | 0.08% | 0.00% | Jun 2026 |
| Stewardship Partners Glb Multi Tax-Eff | 678.00 | 0.03% | 0.00% | Jun 2026 |
Top institutions holding SBFM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jane Street Group LLC | 15.0K | 0.35% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 385.00 | 0.01% | -73.68% | Jun 2026 |
| SBI Securities Co Ltd | 162.00 | 0.00% | -11.48% | Jun 2026 |
| NATIONAL BANK OF CANADA /FI/ | 5.00 | 0.00% | +400.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 2.00 | 0.00% | 0.00% | Jun 2026 |
| TD Waterhouse Canada Inc | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Strive Financial Group ,LLC | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Commonwealth Equity Services, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Sageview Advisory Group LLC | 0.00 | 0.00% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
| XTX Topco Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
| CoreCap Advisors, LLC | 0.00 | 0.00% | 0.00% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Sunshine Biopharma Inc company profile
- Company name
- Sunshine Biopharma Inc
- Ticker
- SBFM.US
- Exchange
- USA Stocks
- Listed since
- Oct 30, 2009
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 50
- Fiscal year end
- December
- Address
- 333 Las Olas Way, Fort Lauderdale, FL, United States, 33301
- Phone
- 954 330 0684
- Website
- sunshinebiopharma.com
About Sunshine Biopharma Inc
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Sunshine Biopharma Inc management
3- Dr. Steve N. Slilaty Ph.D.Chairman, President & CEO · born 1952
- Mr. Camille SebaalyCFO, Secretary & Director · born 1959
- Mr. Michel RoyChief Commercial Officer · born 1968